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The potential role of calcium entry blockers in the pre-
vention of life-threatening arrhythmias associated with
acute myocardial ischemia and reperfusion is still con-
troversial. In 98 anesthetized cats, the effect of diltiazem
was examined in two experimental models. In protocol
I, ventricular tachycardia or fibrillation was consistently
induced by the interaction between a 2 minute coronary
artery occlusion and a 30 second left stellate ganglion
stimulation. After three trials under control conditions,
if the same pattern of arrhythmia was induced, the drug
under study was administered and three additional trials
were performed. In 16 animals the administration of
saline solution did not modify the pattern of arrhyth-
mias. In contrast, diltiazem (0.1 mg/kg body weight plus
0.2 mg/kg per h) abolished both ventricular tachycardia
and fibrillation that had occurred in 64 and 36%, re-
spectively, of the cats in the control state.
In protocol II, a 20 minute coronary artery occlusion
was released in three groups; one served as the control
The prevention of sudden death in patients with coronary
artery disease requires interventions directed toward some
of the most critical events that lead to ventricular fibrillation .
Analysis of Holter electrocardiographic recordings in pa-
tients who died suddenly has provided evidence suggesting
that acute myocardial ischem ia precedes the terminal ar-
rhythmia in a large percent of cases (I) . Because of the
relatively low sensitivity of Holter recordings for revealing
changes in ST-T waves, this percent is likely to be under-
estimated. Signs of sympathetic hyperactivity have been
found (2) among patients who develop ventricular fibrilla-
tion in the first hour after myocardial infarction, and the
critical role of the sympathetic nervou s system in the genesis
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group, one received diltiazem 15 minutes before occlu-
sion and one received diltiazem 3 minutes before reper-
fusion. The incidence of reperfusion ventricular fibril-
lation was 62% (16 of 26) in the control group. It was
significantly (p < 0.05) reduced by diltiazem adminis-
tered before the occlusion to 25% (4 of 16), whereas it
was not affected when diltiazem was administered just
before reperfusion (7 [47%1of 15).
These results indicate that diltiazem exerts a striking
protective effect against the malignant arrhythmias in-
duced by the combination of acute myocardial ischemia
and sympathetic hyperactivity. Diltiazem was also ef-
fective in reducing the incidence of life-threatening re-
perfusion arrhythmias. The potential of this drug for
reducing the incidence of malignant arrhythmias in pa-
tients with ischemic heart disease warrants careful eval-
uation.
(J Am Coil Cardiol 1986;8:661-8)
of lethal arrhythmias has been amply documented (3,4).
These clinical observations underscore the relevance of the
very early ischemic arrhythmias in experimental models ,
the so-called phase IA arrhythmias (5).
There is strong experimental evidence (6) that reperfu sion
of the ischemic myocardium is associated with a very high
inciden ce of ventricular fibrillation. The clinical evidence
is not as abundant , but a growin g number of report s (7,8 )
have related the termination of ischemic episodes to the
occ urrence of malignant arrhythmi as in humans .
It would be reassuring if a drug chosen to prevent sudden
death in patients with coronary artery disease was effective
against both ischemic and reperfu sion arrh ythmias; how-
ever , the latter are resistant to many common antiarrhythmic
drugs (9, 10). Accordingly, we decid ed to test potentially
useful agents with two protocols. In the first protocol , life-
threatening ventricular arrhythmias are induced by the in-
teract ion between a brief ischemic episode and sympathetic
hyperactivity (11,12); in the seco nd . ventricular arrhythmias
are induced by release of a coronary artery occlusion of 20
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minutes' duration (13). Calcium entry blockers are already
widely used in the management of patients with coronary
artery disease and, although their antiarrhythmic efficacy is
still controversial (14), they represent a logical group of
drugs to examine. In this study we evaluated the effects of
diltiazem (15,16).
Methods
Experiments were performed on 98 adult cats weighing
2.0 to 3.6 kg. The study was performed in accordance with
animal welfare regulation at the authors' institution and with
the guiding principles of the American Physiological So-
ciety. Details for the two protocols are given separately.
Protocol I: Coronary Artery Occlusion
and Sympathetic Stimulation
Surgical preparation. Thirty-three cats were sedated
with ketamine (20 mg/kg body weight intramuscularly) and
anesthetized with alpha-chloralose (70 mg/kg intrave-
nously). Ventilation with room air was maintained by means
of a tracheal cannula connected to a Harvard model 607
respirator. Tidal volume and respiratory rate were adjusted
to keep blood gases and pH within physiologic range
throughout the experiment. The body temperature was con-
stantly recorded by a rectal thermistor probe (YSI43TA) and
maintained in the normal range by means of a heating pad
and ali infrared lamp.
Polyethylene catheters were inserted in a femoral artery
and vein for blood pressure recording and drug administra-
tion. The second to fifth ribs were removed on the left side.
Through this opening the left stellate ganglion was carefully
isolated from the surrounding tissue, without severing its
connections, and prepared for electrical stimulation. The
right stellate ganglion was removed to decrease cardiac elec-
trical stability (17) and to prevent excessive heart rate changes
reflexly mediated, during the stimulation of the left stellate
ganglion. A small pericardial incision was performed and
the anterior descending branch of the left coronary artery
was isolated at its origin; care was taken to avoid damage
to surrounding nerves. A thread was gently passed around
the vessel and its ends were inserted in a rigid polyethylene
tube so that, by pulling them firmly, complete occlusion of
the coronary artery could be produced.
A Grass S88 pulse generator connected to two stimulus-
isolation units (Grass SIU5) was employed for electrical
stimulation of the left stellate ganglion (square wave pulses
of 3 ms, 15 to 20 Hz and 15 to 20 V) and for unipolar atrial
pacing through a needle inserted in the right atrial appen-
dage. Defibrillation, whenever necessary, was accom-
plished using a Lifepak 6S defibrillator (5 to 10 J internal
shock).
Experimental protocol. Each experiment consisted of
six to eight trials. In each trial the left anterior descending
coronary artery was occluded for 2 minutes. The left stellate
ganglion was stimulated for 30 seconds at the beginning of
the last minute of occlusion (Fig. 1). If the combination of
ischemia and sympathetic stimulation did not elicit ventric-
ular arrhythmias, the duration of occlusion was increased
to a maximum of 3 minutes. If ventricular arrhythmias were
not elicited or were not consistent, the cat was excluded
from the study (n = 6). If ventricular arrhythmias, similar
in quantity and quality, occurred in three consecutive trials,
the drug under study was administered and three additional
identical trials were performed. In four animals atrial pacing
was used to keep the heart rate constant during the postdrug
trials. Each trial was followed by a 15 minute interval to
allow complete recovery of the preparation. Previous data
(11) indicated that if arrhythmias are induced for three con-
secutive trials, the same type of arrhythmia is reproducibly
induced for at least four or five additional trials.
Sixteen cats received an injection of saline solution after
the three control trials, whereas diltiazem was administered
to the 11 other cats in Protocol I. Therefore, reproducibility
of arrhythmias was assessed by the injection of saline so-
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Figure 1. Diagram of the experimental model
with an example of the electrocardiographic
changes. The letters a to e indicate the phases
of the occlusion/stimulation protocol during
which the electrocardiogram was recorded.
Ventricular arrhythmias appear during the left
stellate ganglion stimulation (LSa stirn) and
persist during the last part of the occlusion.
The electrocardiogram returns to control in a
few seconds after the release of the coronary
artery occlusion.
-30 o 30 60 90 120 +150 sec
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lution and the efficacy of diltiazem was tested by means of
internal control analysis .
Protocol II: Coronary Artery Occlusion
and Reperfusion
Surgical preparation. Sixty-five cats were anesthetized
and ventilated as previously described . Polyethylene cath-
eters were inserted in a femoral artery and vein. The fifth
rib was removed on the left side. Throu gh this opening a
pericardial incision was performed and the left anterior de-
scending coronary artery was isolated at its origin. A suture
was gently passed around the vessel and its ends were passed
through a polyethylene tube.
Experimental protocol. Coronary artery occlusion was
obta ined by pulling the two ends of the suture holding the
end of the tube against the vessel and securing the snare
with a bulldog clamp. The occlu sion was maintained for 20
minute s. No attempt was made to resuscitate the animal s
that developed fibrillation dur ing occlusion (n = 8). In the
animals surviv ing the occlusion, abrupt reperfusion was ob-
tained by releasing the clamp and loosening the suture .
Reperfusion of the previously ischemic myocardium was
confirmed by observing the return within seconds of a red-
dish color of the left ventricular free wall. Arrhythmias
occurring within I minute after release of the coronary artery
occlusion were defined as reper fusion arrhythmias . After
reperfu sion , data were recorded for an additional 10 min-
utes.
Three groups were studied . Thirt y-one cats served as
control group; 16 cats received diltiazem 15 minutes before
coronary artery occlusion (diltiazem preocclusion group)
and 18 cats received diltiazem 3 minutes before reperfusion
(diltiazem prereperfusion group ).
Drug dosage. Diltiazem (Lirca Synthelabo) was admin-
istered in a dose of O. I mg/kg as a bolus injection, followed
by an infusion at a rate of 0 .2 rug/kg per h. This dosage
produced an average lengthening of the PR interval of the
electrocardiogram by 20 to 40% and a reduction in blood
pressure of 10 to 20 mm Hg: these are reliable markers of
the biologic effect of the drug (18).
Data recording. Aorti c blood pressure (Statham P231D
pressure transducer), instantaneous heart rate, surface elec-
trocardiogram and an intracavitary electrogram (for a better
distinction between supraventr icular and ventricular arrhyth-
mias) were recorded on a Brush recorder (model 260) or a
Beckman recorder (model R612) and simultaneously dis-
played on a Tektronix storage osci lloscope (model 511).
The signals were also stored on a Hewlett-Packard 3960A
or a Racal Store 7DS magnetic tape recorder for subsequent
analysis .
Definitions. For statistical purposes, arrhythmias ob-
served during occlusion and reperfusion were classified into
the followin g categories: ventricular fibrillation; ventricular
tachycardia defined as four or more consecutive premature
beats at a rate greater than 200 beats/min ; and premature
ventricular complexes. In the reperfusion experiments ven-
tricular tachycardia s were further defined as sustained (du-
ration 2:: 30 seconds) or nonsustained « 30 seconds) be-
cause of their different hemodynamic consequences. In these
animals we also evaluated the incidence of arrhythmias that
occurred dur ing the 20 minutes of ischemia. Arrhythmias
were classified as phase IA if their onset was within the
first I0 minutes of coronary artery occlusion and as phase
IB if their onset was in the last 10 minutes of ischemia.
Statistics. Statistical analysis of the hemodynamic val-
ues was performed using a paired t test in protocol I and
one-way analysis of variance plus a modified t test in pro-
tocol II; arrhythmia incidence was evaluated by the chi-
square test with Yates ' correct ion when needed.
Results
Protocol / : Coronary Artery Occlusion
and Sympathetic Stimulation
In 6 of the 33 cats, either arrhythmias could not be re-
producibly induced or hemodynamic deterioration occurred .
These animals were excluded from the study .
Saline solution was tested in 16 animals . In this group
during control trials, ventricular fibrillation was induced in
six cats (38%), ventricular tachycardia in seven (44%) and
premature ventricular complexes in three (18%) . The admin-
istration of saline solution did not alter the occurrence of
arrhythmias (Fig. 2) .
Diltiazem was tested in 11 animals. The drug reduced
slightly both basal heart rate (from 177 ± 27 to 150 ± 22
beats/min; p < 0.02) and blood pressure (from 113 ± 32
to 100 ± 20 mm Hg; p < 0 .01). The heart rate response
to sympathetic stimulation was also blunted by the drug
(change in heart rate decreased from 23 ± 17 to II ± IS
beats/min ; p < 0.02) whereas the change in blood pressure
was not affec ted (change in blood pressure increased from
33 ± 17 to 37 ± 26 mm Hg, p = NS). The antiarrhythmic
effect of diltiazem in this preparation was striking (Fig. 3).
In the control trials , ventricular fibrillation was reprodu cibly
induced in four cats (36%) and ventricular tachycard ia in
seven (64%). After injection of the drug , there was no
instance of ventricular fibrillation or ventricular tachycardia;
not even isolated premature ventricular complexes occurred.
In four cats the trials after diltiazem were performed
while the heart was paced at a rate comparable with the
maximum achieved during the control trials. The effect of
the drug was not modified by the higher heart rate . In a fifth
cat, pacing the heart after diltiazem administration elicited
a 3: 2 second degree Mobit z I atrioventricular block; there-
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Figure 2. Protocol I. Effects of administration of saline solution.
Each square represents the result of at least three trials in each
cat. Each arrow represents one experiment. The squares on the
left show the results observedduring the threecoronary occlusions
plus sympathetic stimulation performedin controlconditions, that
is, before saline administration. The squares on the right show
the results observed when three additional trials are performed
after saline administration. It is evident that the injection of saline
solution in 16 cats does not modify the response to coronary oc-
clusion plus sympathetic stimulation. The numbers in the squares
indicate the number of premature ventricular complexes. VF
ventricularfibrillation; VT = ventricular tachycardia.
fore the occlusion and sympathetic stimulation trial was
performed without pacing.
Protocol II: Coronary Artery Occlusion
and Reperfusion
Hemodynamic data (Table 1). All three groups of these
65 animals had homogenous baseline values for heart rate
and blood pressure as assessed by analysis of variance.
Diltiazem injected either before or after occlusion transiently
decreased both blood pressure and heart rate (p < 0.01).
However, heart rate and blood pressure values at the moment
of reperfusion, although slightly lower in the diltiazem-
treated group, were not significantly different from those in
the control group.
Ischemic arrhythmias (Table 2). During the 20 minutes
of ischemia preceding reperfusion, ventricular fibrillation
occurred in 5 (16%) of the 31 cats in the control group,
Figure 3. Protocol I. Effect of diltiazem in II cats. Format and
abbreviations as in Figure 2.
whereas it was never observed in the 16 cats in the diltiazem
preocclusion group and it occurred in 3 (17%) of the 18
cats in the diltiazem prereperfusion group. Moreover, in the
animals pretreated with diltiazem before occlusion there was
also a significantly lower incidence of ventricular tachy-
cardia and premature ventricular complexes. The drug af-
forded protection against both phase 1A and 1B arrhythmias.
Reperfusion arrhythmias (Table 3). Ventricular fi-
brillation occurred in 16 (62%) of 26 cats in the control
group, and in 7 (47%) of 15 when diltiazem was given
before reperfusion but was significantly reduced by dilti-
azem injected before ischemia (4 [25%] of 16) (p < 0.05).
Also, the mode of onset of ventricular fibrillation was ap-
parently affected by diltiazem. In 12 (75%) of 16 control
animals, ventricular fibrillation occurred as a degeneration
of a preceding ventricular tachycardia. This was never the
case among those cats that received diltiazem before occlu-
sion and that had ventricular fibrillation. In this group the
onset of ventricular fibrillation was always sudden
(Fig. 4). When sustained ventricular tachycardia is taken
into account, the protective effect of diltiazem injected be-
fore coronary artery occlusion becomes even more striking.
The combined incidence of ventricular fibrillation and
sustained ventricular tachycardia was 93% in the control
group, 74% in the diltiazem prereperfusion group and 38%
in the diltiazem preocclusion group. This difference with
lACC Vol. 8, No.3
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Table 1. Heart Rate and Blood Pressure in the Three Groups of Cats in Protocol II
Heart Rate (beats/min) Blood Pressure (rnm Hg)
Basal Before Coronary Before Basal Before Coronary Before
Value Artery Occlusion Reperfusion Value Artery Occlusion Reperfusion
Control group (n = 31) 214 ± 33 212 ± 24 206 ± 42 135 ± 39 130 ± 27 lIS ± 37
Diltiazem groups 207 ± 27 185 ± 21* 185 ± 27* 125 ± 35 108 ± 20t 99 ± 29t
Preocclusion (n = 16)
Prereperfusion (n = 18) 215 ± 29 214 ± 30 187 ± 27* 140 ± 32 135 ± 28 110 ± 30t
*p < 0.01 versus basal values; tp < 0.05 versus basal values. Diltiazem groups: Preocclusion = group of cats receiving diltiazem before coronary
artery occlusion; Prereperfusion = group of cats receiving diltiazem before reperfusion.
Table 2. Incidence of Arrhythmias During the 20 Minutes of
Ischemia in the Three Groups of Cats in Protocol II
respect to the preocclusion group is highly significant (p <
0.002 versus control group) (Fig. 5).
Discussion
This study demonstrates that the calcium entry blocker
diltiazem is quite effective in preventing life-threatening
arrhythmias induced by either acute myocardial ischemia or
reperfusion. The different protocols used require separate
comments.
Diltiazem and ischemic arrhythmias. The effect of
diltiazem in the prevention of arrhythmias related to acute
myocardial ischemia has been examined in a few studies.
Patterson et al. (19) found no effect of diltiazem on ven-
tricular fibrillation threshold under either normal or ischemic
conditions, whereas Anastasiou-Nana et al. (20) had dif-
ferent results. They observed after diltiazem administration
an increase in ventricular fibrillation threshold in the absence
of ischemia, and less change in ventricular fibrillationthreshold
induced by ischemia. This discrepancy may partly depend
on the use in both studies of a "train of pulses" to measure
ventricular fibrillation threshold. This technique is contro-
versial and may produce inconsistent results (21). Patterson
et al. (19) also found no protection with diltiazem for ar-
rhythmias induced by programmed electrical stimulation;
however, there is still uncertainty as to the exact relation
between ischemia-induced and electrically induced arrhyth-
mias.
Clusin et al. (18) found that diltiazem delays from 138
to 295 seconds the time to onset of ventricular fibrillation
*p < 0.05. Abbreviations as in Table I.
Table 3. Incidence of Reperfusion Arrhythmias in the Three
Groups of Cats in Protocol II
VF VTs VTns PVCs No Arrhythmias
(%) (%) (%) (%) (%)
Control group (n = 26) 62 31 7 0 0
Diltiazem groups 25* 12.5 31 19 12.5
Preocclusion
(n = 16)
Prereperfusion 47 27 26 0 0
(n = IS)
*p < 0.05 versus control animals. The number of animals in each
group differs from that in Table 2 because ventricular fibrillation occurred
during ischemia in five animals in the control group and thn;e animals in
the group treated before reperfusion. PVCs = premature ventricular com-
plexes; VF = ventricular fibrillation; VTns = nonsustained ventricular
tachycardia; VTs = sustained ventricular tachycardia (> 30 seconds); other
abbreviations as in Table I.
after occlusion of both the left anterior descending and the
left circumflex coronary artery. The model of global isch-
emia is questionable in terms of its relevance to clinical
sudden death, and the significance of postponing ventricular
fibrillation for a few minutes might be limited. Nonetheless,
this latter study can be viewed as suggesting some protective
effect of diltiazem. The model used in these experiments
has the limitation common to such acute studies, namely,
the use of anesthesia in an open chest preparation. In ad-
dition, the removal of the right stellate ganglion has been
used to increase cardiac electrical instability (17,22); this
helps to overcome the anesthesia-induced depression of
sympathetic reflexes.
In our experiments the striking antiarrhythmic efficacy
of diltiazem probably depended on a combination of actions
that can antagonize the arrhythmogenic effects of neural
activation on an ischemic myocardium. In our model, the
enhancement of arrhythmias by the alteration of sympathetic
input may depend on one or more of the following mech-
anisms: I) an extension of the ischemic area as a result of
left stellate ganglion stimulation (23); 2) direct electro-
physiologic effects of neural stimulation to further lower
the threshold for ventricular fibrillation (24) or to facilitate
the occurrence of focal mechanisms on the border zone, or
67
31*
89
Total
Arrhythmias
(%)
61
45
19*
Phase IB
Arrhythmias
(%)
61
51
19*
Phase IA
Arrhythmias
(%)
Control group
Diltiazem groups
Preocclusion
Prereperfusion
666 SCHWARTZ ET AL
DILTIAZEM AND LIFE-THREATENING ARRHYTHMIAS
lACC Vol. 8. No. 3
September 1986:661- 8
ECG MW,t
A
200
o
Figure 4. Protocol II. Examples of reperfusion ven-
tricular fibrillation with a sudden onset (A) or pre-
ceded by ventricular tachycardia (8). The second
tracing in A and 8 follows reperfus ion by 11 and 10
seconds, respectively. Note the sudden decrease in
blood pressure (BP) in A coincident with the onset
of ventricular fibrillation , whereas in 8 blood pres-
sure decreases mildly during ventricular tachycardia
and falls abruptly only when ventricular fibrillation
begins. ECG = electrocardiogram.
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both (25) ; and 3) facilitation of the increase in intracellular
calcium concentration which in tum may enhance arrhyth-
mias related to abnormal autom aticity-triggered firing or so-
called slow respon ses. Diltiazem is certainly able to deepl y
interfere with the effect of sympathetic activation on the
Figure 5. Protocol II. Effect of diltiazem on reperfusion arrhyth-
mias in the three groups, showing the incidence of ventricular
fibrillation (VF) (dotted columns) and sustained ventricular tachy-
cardia (VTs) (hatched columns). The administration of diltiazem
before coronary artery occlusion (pre CAO) significantly reduced
the incidence of malignant ventricular arrhythmias. No protective
effec t was observed when the drug was administered before re-
perfusion (pre REP).
ischemic myocardium , particularly with the first (26) and
the third (18) of these mechanisms. These properties might
also explain the effectiveness of diltiazem on the ischemic
arrhythmias of the 20 minute occlusion without sympathetic
stimulation, in which a spontaneous release of catechol-
amines by reflex act ivation could occ ur (27 ). However , we
cannot rule out other potential protective activities; for ex-
ample, diltiazem has been shown to reduce conduction delay
(28) , an effect usually viewed as antiarrhythmic. It is un-
likely that the diltiazem-induced reductions in heart rate and
blood pressure played a major role because I) pacing the
heart to the highest rate observed during sympathetic stim-
ulation did not modify the protective effect of diltiazem ,
and 2) the blood pressure responses to sympathetic stimu-
lation were unaffect ed by diltiazem . Although the mecha-
nisms involve d have not yet been elucidated , it is important
for both theoretical and pract ical reasons to appreciate that ,
against the same type of arrhythmi as, class I antiarrh ythm ic
drugs have been totally ineffective, alpha- and beta-adre-
nergic blocking agent s have conferred good but incomplete
protection and total prevention of ventricular tachycardi a
and ventricular fibrillat ion has been obtained only by arnio-
darone and the other well known calcium channel blocker ,
verapamil (12) .
Diltiazem and reperfusion arrhythmias. Diltiazem
proved to be of considerable , although not complete, effi-
cacy in the prevention of reperfusion arrhythmias. The re-
duction of the incidence of ventricular fibrillation from 62
to 25% and the major reduction of the combined incidence
pre CAO pre REP
Diltiazem
rr: p<O.002-,
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of ventricular fibrillat ion and sustained ventricular tachy-
card ia from 93 to 38% is significant because reperfu sion
arrhythmi as are difficult to prevent ; that is , they are resistant
to both Class I antiarrhythmic drugs and beta-adrenergic
blocking agents (6) .
Brook s et al. (29) observed a protective effect of vera-
pamil in preventing a reperfu sion-induced decrease in ven-
tricul ar fibrillation threshold ; Ribeiro et al. (30) and Naito
et al. (10) observed, respectively, the efficacy and failure
of verapamil in preventing reperfusion arrhythmias. Shee-
han and Epstein (31), using a 30 minute coronary artery
occlusion, reported lack of efficacy of both diltiazem and
nifedipine in preventing reperfu sion ventricular fibrillation
in dogs. Because few studies have been performed, the
inconsistency of results does not allow definitive conclu-
sions. However, the fact that species and duration of oc-
clusion (6) were not homogeneous among the studies may
at least partiall y account for the different results.
In our study, diltiazem was effect ive only when it was
administered before coronary arte ry occlusion. This indi-
cates that the presence of the drug in the area that is going
to become ischemic is essential to prevent the arrhythmias
produced by reperfusion. Diltiazem is likely to quantita-
tively reduce the ischemic injury produced durin g coronary
artery occlusion; indeed, this drug has been shown to greatly
attenuate the decrease in adenosine tripho sphate (ATP) (32),
dim inish the inhibition of anaerobic glyco lysis and lower
the cardiac levels of lactic and free fatty acids, thus mini-
mizing the metabol ic consequence s of acute myocard ial
ischemia . This anti-is chemic activi ty could reduce the elec-
trical inhomogeneity that seems to play such a critical role
in the development of reperfu sion arrhythmias. In addition ,
a direct effect in preventing the massive intracellular calcium
overlo ad that occurs during reperfusion (33) should be con-
sidered. This latter phenomenon can be prevented only if a
calcium channel blocker is admini stered before coronary
artery occlusion (34).
Clinical implications. If one considers that the very
early phase of acute myocard ial ischemia is quite often
associated with reflexly augmented sympathetic activity, the
ability of diltiazem to prevent malignant arrhythmias in-
duced by the combination of these two factors should not
be overlooked . On the other hand , the protective effect of
diltiazem on reperfusion arrhythmi as has, in addition to its
theoretical implications, some practical significance becau se
the calcium channel blockers are widely used in the man-
agement of patients with variant angina, a patient group at
great risk for reperfu sion arrhythmias . Even with the caution
necessary in extrapolating experimental results to the clin-
ical setting, the combined results of our study on the effects
of diltiazem on ischem ia and reperfu sion arrhythmias pro-
vide a rationale for a thorou gh evaluation of diltiazem in
patients with coronary artery disease at high risk for sudden
death .
We express our gratitude to Ralph Lazzara , MD for reviewing the manu-
script and for helpful criticism. We are also grateful to Luciana Lucchin i
for typing the manuscript and Car la Zanchetti for assistance in preparing
the figures .
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